,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-09-16 08:00:00,The following are the top rated Healthcare stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig .,0.11987075954675674,0.004934975877404213,0.8751943111419678,neutral,0.11493578553199768
1,2018-09-16 08:00:00,"This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.",0.44186264276504517,0.010622658766806126,0.5475146770477295,neutral,0.4312399923801422
2,2018-09-16 08:00:00,NEOGEN CORPORATION ( NEOG ) is a mid-cap growth stock in the Medical Equipment & Supplies industry.,0.7315717935562134,0.01185261458158493,0.2565756142139435,positive,0.7197191715240479
3,2018-09-16 08:00:00,The rating according to our strategy based on Martin Zweig is 85% based on the firm's underlying fundamentals and the stock's valuation.,0.0344078429043293,0.005085877142846584,0.9605062007904053,neutral,0.02932196483016014
4,2018-09-16 08:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
5,2018-09-16 08:00:00,"Company Description: Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety.",0.031064121052622795,0.005070481915026903,0.963865339756012,neutral,0.02599363960325718
6,2018-09-16 08:00:00,The Company operates through two segments: Food Safety and Animal Safety.,0.014216883108019829,0.007602034602314234,0.9781810641288757,neutral,0.006614848505705595
7,2018-09-16 08:00:00,"The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation.",0.020404905080795288,0.006136901210993528,0.9734582304954529,neutral,0.014268003404140472
8,2018-09-16 08:00:00,"The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including a range of consumable products marketed to veterinarians and animal health product distributors.",0.016441073268651962,0.006247217301279306,0.9773116707801819,neutral,0.010193856433033943
9,2018-09-16 08:00:00,The Animal Safety segment also provides genetic identification services.,0.022934140637516975,0.005883115343749523,0.9711827039718628,neutral,0.017051026225090027
10,2018-09-16 08:00:00,"Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents and disease in and around agricultural, food production and other facilities.",0.03210204094648361,0.005789498798549175,0.9621084332466125,neutral,0.026312541216611862
11,2018-09-16 08:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
12,2018-09-16 08:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
13,2018-09-16 08:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

ABIOMED, INC. ( ABMD ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.43621203303337097,0.00858487468212843,0.5552030801773071,neutral,0.4276271462440491
14,2018-09-16 08:00:00,The rating according to our strategy based on Martin Zweig is 77% based on the firm's underlying fundamentals and the stock's valuation.,0.03034227155148983,0.005309665575623512,0.9643480181694031,neutral,0.025032605975866318
15,2018-09-16 08:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
16,2018-09-16 08:00:00,"Company Description: ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices.",0.03791738301515579,0.006155435461550951,0.9559271931648254,neutral,0.03176194801926613
17,2018-09-16 08:00:00,The Company offers care to heart failure patients.,0.06398126482963562,0.0056616803631186485,0.930357038974762,neutral,0.0583195835351944
18,2018-09-16 08:00:00,"The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart.",0.03957038000226021,0.005350144580006599,0.9550794363021851,neutral,0.03422023355960846
19,2018-09-16 08:00:00,"The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.",0.3127593994140625,0.006911749020218849,0.6803288459777832,neutral,0.3058476448059082
20,2018-09-16 08:00:00,"The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000.",0.02572770044207573,0.004518821369856596,0.9697534441947937,neutral,0.021208878606557846
21,2018-09-16 08:00:00,"The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.",0.029973052442073822,0.004718397278338671,0.9653086066246033,neutral,0.02525465562939644
22,2018-09-16 08:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
23,2018-09-16 08:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
24,2018-09-16 08:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

AMGEN, INC. ( AMGN ) is a large-cap growth stock in the Biotechnology & Drugs industry.",0.4738428294658661,0.00993863120675087,0.5162185430526733,neutral,0.4639042019844055
25,2018-09-16 08:00:00,The rating according to our strategy based on Martin Zweig is 77% based on the firm's underlying fundamentals and the stock's valuation.,0.03034227155148983,0.005309665575623512,0.9643480181694031,neutral,0.025032605975866318
26,2018-09-16 08:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
27,2018-09-16 08:00:00,Company Description: Amgen Inc. is a biotechnology company.,0.012834355235099792,0.008020137436687946,0.9791455268859863,neutral,0.004814217798411846
28,2018-09-16 08:00:00,"The Company discovers, develops, manufactures and delivers various human therapeutics.",0.04877732694149017,0.004117672797292471,0.9471049308776855,neutral,0.044659655541181564
29,2018-09-16 08:00:00,It operates in human therapeutics segment.,0.03858906030654907,0.005032994784414768,0.9563779234886169,neutral,0.03355606645345688
30,2018-09-16 08:00:00,"Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).",0.017958298325538635,0.006075523793697357,0.975966215133667,neutral,0.011882774531841278
31,2018-09-16 08:00:00,"It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.",0.023292776197195053,0.005788520444184542,0.9709186553955078,neutral,0.0175042562186718
32,2018-09-16 08:00:00,"Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.",0.07398897409439087,0.007534234784543514,0.9184767603874207,neutral,0.06645473837852478
33,2018-09-16 08:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
34,2018-09-16 08:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
35,2018-09-16 08:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BAXTER INTERNATIONAL INC ( BAX ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.6153402328491211,0.010300562717020512,0.3743591904640198,positive,0.605039656162262
36,2018-09-16 08:00:00,The rating according to our strategy based on Martin Zweig is 77% based on the firm's underlying fundamentals and the stock's valuation.,0.03034227155148983,0.005309665575623512,0.9643480181694031,neutral,0.025032605975866318
37,2018-09-16 08:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
38,2018-09-16 08:00:00,"Company Description: Baxter International Inc., through its subsidiaries, provides renal and hospital products.",0.016776859760284424,0.00666993809863925,0.9765532612800598,neutral,0.010106921195983887
39,2018-09-16 08:00:00,The Company operates through two segments: Hospital Products and Renal.,0.015520949847996235,0.00666307145729661,0.9778159856796265,neutral,0.008857877925038338
40,2018-09-16 08:00:00,"Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.",0.023244887590408325,0.005879237316548824,0.9708758592605591,neutral,0.017365649342536926
41,2018-09-16 08:00:00,"The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis ( HD ), continuous renal replacement therapy (CRRT) and additional dialysis services.",0.13980115950107574,0.004776298999786377,0.8554225564002991,neutral,0.13502486050128937
42,2018-09-16 08:00:00,"Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.",0.01395258679986,0.007541074883192778,0.9785063862800598,neutral,0.006411511916667223
43,2018-09-16 08:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
44,2018-09-16 08:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
45,2018-09-16 08:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

CHARLES RIVER LABORATORIES INTL.",0.13230198621749878,0.012084713205695152,0.8556132912635803,neutral,0.12021727114915848
46,2018-09-16 08:00:00,INC (CRL) is a mid-cap growth stock in the Biotechnology & Drugs industry.,0.7222952246665955,0.012309230864048004,0.26539552211761475,positive,0.7099859714508057
47,2018-09-16 08:00:00,The rating according to our strategy based on Martin Zweig is 77% based on the firm's underlying fundamentals and the stock's valuation.,0.03034227155148983,0.005309665575623512,0.9643480181694031,neutral,0.025032605975866318
48,2018-09-16 08:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
49,2018-09-16 08:00:00,"Company Description: Charles River Laboratories International, Inc. is an early-stage contract research company.",0.030281540006399155,0.005514189135283232,0.9642042517662048,neutral,0.024767350405454636
50,2018-09-16 08:00:00,"The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.",0.10538201034069061,0.0043517523445189,0.8902661800384521,neutral,0.10103026032447815
51,2018-09-16 08:00:00,"The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).",0.019753118976950645,0.005813432391732931,0.974433422088623,neutral,0.013939686119556427
52,2018-09-16 08:00:00,The RMS segment includes Research Models and Research Model Services.,0.012622000649571419,0.006800569593906403,0.9805773496627808,neutral,0.005821431055665016
53,2018-09-16 08:00:00,The DSA segment includes Discovery Services and Safety Assessment.,0.013655124232172966,0.006797403562813997,0.9795475602149963,neutral,0.006857720669358969
54,2018-09-16 08:00:00,"The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing.",0.01320639718323946,0.006981737911701202,0.9798118472099304,neutral,0.006224659271538258
55,2018-09-16 08:00:00,The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.,0.07489992678165436,0.004556737374514341,0.920543372631073,neutral,0.07034318894147873
56,2018-09-16 08:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
57,2018-09-16 08:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
58,2018-09-16 08:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Martin Zweig has returned 493.78% vs. 190.38% for the S&P 500.",0.7684938907623291,0.14314022660255432,0.08836591988801956,positive,0.6253536939620972
59,2018-09-16 08:00:00,"For more details on this strategy, click here

About Martin Zweig : During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest.",0.8395671248435974,0.017058880999684334,0.1433740258216858,positive,0.8225082159042358
60,2018-09-16 08:00:00,"Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses.",0.1772042065858841,0.007844403386116028,0.8149514198303223,neutral,0.16935980319976807
61,2018-09-16 08:00:00,"He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in ""Dirty Harry"", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.",0.08425553888082504,0.01607971452176571,0.8996647596359253,neutral,0.06817582249641418
62,2018-09-16 08:00:00,About Validea : Validea is an investment research service that follows the published strategies of investment legends.,0.01593991555273533,0.006665502674877644,0.9773945808410645,neutral,0.009274412877857685
63,2018-09-16 08:00:00,"Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.",0.08751808106899261,0.010206557810306549,0.9022753238677979,neutral,0.07731152325868607
64,2018-09-16 08:00:00,"For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.009221813641488552,0.018771808594465256,0.9720064401626587,neutral,-0.009549994952976704
